

Freedom of Information Request: Our Reference CTMUHB_384_21

You asked:

Q1 – In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant injection)
- Lorviqua (Lorlatinib)

Q2 – In the past 6 months (latest 6 months available) how many patients have received the following immunoglobulin treatments (for any disease):

- Cuvitru
- Gammanorm
- Gamunex
- Hizentra
- Hyqvia
- Intratect
- Kiovig
- Octagam
- Privigen
- Subgam

Our response:

Please see provided below tables populated with the number of patients treated, recorded by Medicines Management during the period of March 21 to August 21.

The information provided relates mainly to the Merthyr & Cynon and Rhondda Taff Ely Localities of the Health Board. However, where data has been available for the Bridgend Locality this has been included. In relation to the Bridgend Locality of the Health Board, patients that may require treatment with the medicines above would possibly be treated within the services of a hospital in a neighbouring Health Board. Therefore, we do not hold that data on our Medicines Management system.

Q1.

Medicine	Number of Patients
Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0

Firazyr (Icatibant injection)	0
Lorviqua (Lorlatinib)	0

Q2.

Medicine	Number of Patients
Cuvitru	0
Gammanorm	0
Gamunex	20
Hizentra	0
Hyqvia	**
Intratect	**
Kiovig	0
Octagam	4
Privigen	17
Subgam	0

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.